Rate My Professor Noah Weisleder

Dr. Weisleder's research specializes in muscle physiology, cardiovascular disease, Alzheimer’s disease, and neuromuscular diseases, with particular emphasis on membrane repair proteins in myositis, skeletal muscle proteostasis, membrane repair in dystrophic models, and therapeutic strategies including protein supplementation for Duchenne muscular dystrophy and C2 domain therapeutics. His investigations into molecular mechanisms of lung injury during mechanical ventilation and neurotoxicity in Alzheimer’s disease models contribute to advancements in regenerative medicine. Funded by the National Institutes of Health, Department of Defense, and private foundations, his work has produced hundreds of publications and informed multiple U.S. and international patents, leading to biotechnology companies such as TRIM-edicine, where he was founder and Chief Scientific Officer. Key publications include "Recombinant MG53 Protein Modulates Therapeutic Cell Membrane Repair in Treatment of Muscular Dystrophy" (Science Translational Medicine, 2012), "Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle to contribute to cell membrane repair" (2009), "Nanodysferlins support membrane repair and binding to TRIM72/MG53 but do not localize to t-tubules or stabilize Ca2+ signaling" (Molecular Therapy Methods & Clinical Development, 2024), and "Enhancing Membrane Repair Using Recombinant MG53/TRIM72 (rhMG53) Reduces Neurotoxicity in Alzheimer’s Disease Models" (Biomolecules, 2025). His honors encompass the Kauffman Foundation Outstanding Postdoctoral Entrepreneur Award, NASA Spaceflight Technology, Applications, and Research (STAR) Scholar designation, Undergraduate Research Mentoring Award (2019), Postdoctoral Mentor of the Year Award (2016), Faculty Achievement Award (2015) from The Ohio State University, and election as President of the Ohio Physiological Society in 2015.